This study’s results could potentially lead to the development of MALAT1-targeted therapies in combination with GLP-1RAs for enhanced NAFLD treatment, and MALAT1 levels might serve as a biomarker for disease progression or treatment response. Here, MALAT1 is linked to metabolic dysfunction-associated steatotic liver disease.